Stockscreener 앱 받기
3.84
1.05%
0.04
시간 외 거래:
3.98
0.14
+3.65%
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, B - GuruFocus.com
Revance Therapeutics sinks amid `going concern' disclosure - MSN
Alpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance and Crown extend merger offer date to November 26 - Investing.com India
Revance Therapeutics gains as Crown Labs further extends tender offer - MSN
Revance and Crown extend merger offer date to November 26 By Investing.com - Investing.com UK
LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR
Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.
Where are the Opportunities in (RVNC) - Stock Traders Daily
Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat
Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks
Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan
Top 10 startups in Dermatology in Bay Area, United States in Nov, 2024 - Tracxn
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
0.93%
3.55%
자본화:
|
볼륨(24시간):